Biological
ALK Grass tablet
ALK Grass tablet is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 32 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Trial of the ALK Grass Tablet in Subjects With Hayfever
NCT00227279
completedphase_3
Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets
NCT00413556
completedphase_1
Tolerability of ALK Grass Tablet in Children
NCT00310453
completedphase_1
Tolerability of Grazax-R in Children
NCT00298701
Clinical Trials (4)
Showing 4 of 4 trials
NCT00227279Phase 3
A Trial of the ALK Grass Tablet in Subjects With Hayfever
NCT00413556Phase 3
Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets
NCT00310453Phase 1
Tolerability of ALK Grass Tablet in Children
NCT00298701Phase 1
Tolerability of Grazax-R in Children
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4